Data highlighting results from $PRTX’s European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic ITP were presented at @EHA_Hematology’s #EHA23. Details here: bit.ly/2JR6ZY1

Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the @EHA_Hematology 23rd Annual Meeting bit.ly/2JR6ZY1 $PRTX #EHA23

“We are encouraged by the data readout of our second confirmatory preclinical study for PRTX-100 in MG and hope to use it to advance our path to clinical development in this indication” - $PRTX Preclinical Director bit.ly/2sOJ5pA

Protalex’s #EMH23 abstract highlighting PRTX-100 Phase 1b clinical data in adult patients with persistent/chronic #ITP will be presented on June 15th. View the abstract here: bit.ly/2s35Zcl $PRTX

Protalex announced preliminary findings that its lead drug candidate PRTX-100 reduced disease activity in a second, confirmatory mouse study of myasthenia gravis (MG) bit.ly/2sOJ5pA $PRTX

Preliminary findings support advancement of PRTX-100 into its third clinical indication, details here: bit.ly/2sOJ5pA $PRTX

Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis bit.ly/2sOJ5pA $PRTX

“We are very pleased to complete enrollment of the 203 Study in Europe and we look forward to presenting the data at the EHA meeting,” commented Dr. Francovitch, $PRTX’s VP, ITP Programs. bit.ly/2IqL1tV #EHA23

Preliminary results from $PRTX’s European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic #ITP will be presented at @EHA_Hematology’S #EHA23 on June 15. Details here: bit.ly/2IqL1tV

Protalex Announces Presentation Highlighting PRTX-100 Phase 1B Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting bit.ly/2IqL1tV $PRTX #EHA23

“We are excited to open cohort four in the U.S. and UK, as it demonstrates progress in our evaluation of PRTX-100 in the treatment of ITP," commented $PRTX VP of #ITP programs, Dr. Richard J. Francovitch bit.ly/2GKnfZ5

The fourth dose cohort of Phase 1/2 study of PRTX-100 in #ITP was initiated after a planned, interim analysis of safety and efficacy data from cohort three. bit.ly/2GKnfZ5 $PRTX

$PRTX has enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the treatment of adults with persistent/chronic #ITP. bit.ly/2GKnfZ5

Protalex initiates fourth cohort dosing of Phase 1/2 study of PRTX-100 in Immune Thrombocytopenia (#ITP). Read the full release: bit.ly/2GKnfZ5 $PRTX

Protalex Announces Completion of $1.425 Million Private Placement, Recapitalization and Entry Into Call Option Agreement With Its Principal Stockholder bit.ly/2F67AGZ

$PRTX President Arnold Kling comments on U.K. regulatory approval to open enrollment in the PRTX-100-202 study previously only open at sites in the U.S. bit.ly/2Dk2LVa

$PRTX received U.K. regulatory approval to open enrollment in the Phase 1/2 study of PRTX-100 in adults with persistent/chronic #ITP, with patient recruitment at several new clinical sites to begin in the coming weeks. bit.ly/2Dk2LVa

$PRTX VP of #ITP programs, Dr. Richard Francovitch, comments on dosing first patient in final and highest dose cohort of the PRTX-100-203 study. bit.ly/2Dk2LVa

One of three patients treated in the fourth dose cohort of $PRTX's European Ph 1B study of PRTX-100 achieved a protocol defined #platelet response. Details: bit.ly/2Dk2LVa #ITP

$PRTX has initiated enrollment in the fifth and highest dose cohort of the Company's European Ph 1B study of PRTX-100 in #ITP. bit.ly/2Dk2LVa